- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04529694
Patient Characteristics and Cognitive vs. Behavioral Therapies for Depression
24. august 2020 opdateret af: Daniel R. Strunk, Ohio State University
PATIENT CHARACTERISTICS AND COGNITIVE BEHAVIOR THERAPY FOR DEPRESSION
This is a retrospective registration.
The study was conducted at The Ohio State University from 2011 to 2012.
This study was approved by an Institutional Review Board at The Ohio State University.
The investigators retroactively registered this trial to facilitate publishing results in journal that now require registration.
Any reference to the study's registration will make it clear that the registration was retroactive.
Cognitive behavior therapy (CBT) has been shown to be an effective treatment for depression.
However, a substantial number of patients do not respond to treatment or continue to be symptomatic at its conclusion.
An important goal of ongoing research is to find ways to enhance treatment outcomes.
One approach to doing this is to modifying existing treatments to individualize the approach to better meet the needs of individual patients.
In this study, the investigators tested two main components of CBT to empirically evaluate patient characteristics that may predict differential response to these components.
By using components of CBT, any suggestions about the strategies that are best suited to different patients are likely be easily implemented by therapists providing CBT.
The two treatment components the investigators examined were: cognitive interventions (e.g., challenging negative automatic thoughts) and behavioral interventions (e.g., engaging in activities to promote a sense of pleasure or accomplishment).
The investigators recruited adults with major depressive disorder and randomized them to a cognitive or behavioral intervention.
After 8 weeks of treatment, patients were randomized again to a cognitive or behavioral intervention.
Consequently, participants were offered a total of 16 weeks of treatment.
Depressive symptoms were assessed with the Beck Depression Inventory-II (BDI-II) and the Hamilton Rating Scale for Depression (HRSD), with the latter being the primary outcome measure.
Several variables that might serve to predict differential response to cognitive and behavioral treatments were also assessed.
The results of this study may help to elucidate how cognitive or behavioral interventions might be selected so as to enhance overall treatment outcomes.
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
42
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Department of Psychology, The Ohio State University
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Diagnosis of major depressive disorder (MDD) according to DSM-IV criteria (APA, 1994)
- Able and willing to give informed consent
Exclusion Criteria:
- History of bipolar affective disorder or psychosis
- Current Axis I disorder other than MDD if it constitutes the predominant aspect of the clinical presentation and if it requires treatment other than that being offered
- History of substance dependence in the past six months
- Subnormal intellectual potential (IQ below 80, testing to be initiated if clinically indicated)
- Clear indication of secondary gain (e.g., court ordered treatment)
- Current suicide risk or significant intentional self-harm in the last six months sufficient to preclude treatment on an outpatient basis
- If clients currently being treated with a medication for depression: (1) no change in medication and a stable dose for at least 1 month prior to their initial assessment; and (2) agreeing to not make changes to medication or medication dose during the study.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Cognitive-only Intervention
This condition includes cognitive interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
|
|
Aktiv komparator: Behavioral-only Intervention
The condition includes behavioral interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in Hamilton Rating Scale for Depression at week 8 and week 16
Tidsramme: Time Frame: Weeks 0-8 and 0-16, assessments occurred at weeks 0, 4, 8, and 16.
|
The Hamilton Rating Scale for Depression is a 17-item interviewer evaluated assessment of depressive symptoms.
Scores range from 0 to 52, with higher scores indicating greater depressive symptoms.
|
Time Frame: Weeks 0-8 and 0-16, assessments occurred at weeks 0, 4, 8, and 16.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in Beck Depression Inventory-II at week 8 and week 16
Tidsramme: Time Frame: Weeks 0-8 and 0-16, assessments occurred at every session through week 16.
|
The Beck Depression Inventory-II is a 21-item self-report measure of depressive symptoms.
Scores range from 0 to 63, with higher scores indicating greater depressive symptoms.
|
Time Frame: Weeks 0-8 and 0-16, assessments occurred at every session through week 16.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
20. oktober 2011
Primær færdiggørelse (Faktiske)
26. juni 2012
Datoer for studieregistrering
Først indsendt
14. august 2020
Først indsendt, der opfyldte QC-kriterier
24. august 2020
Først opslået (Faktiske)
28. august 2020
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
28. august 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. august 2020
Sidst verificeret
1. august 2020
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2011B0342
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
We will consider requests for data sharing, pending approval from our IRB.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Større depressiv lidelse
-
Shalvata Mental Health CenterUkendt
-
Yonsei UniversityAfsluttet
-
Section for Affective Disorders; Northern Stockholm...Afsluttet
-
Gangnam Severance HospitalAfsluttetMajor Depressive Disorder (MDD)Korea, Republikken
-
Seasons Biotechnology (Taizhou) Co., Ltd.AfsluttetMajor Depressive Disorder (MDD)Indien
-
Repurposed Therapeutics, Inc.Ukendt
-
GlaxoSmithKlineAfsluttetMajor Depressive Disorder (MDD)Forenede Stater
-
AccexibleRekrutteringMajor Depressive Disorder (MDD)Spanien
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Ikke rekrutterer endnuMajor Depressive Disorder (MDD)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RekrutteringMajor Depressive Disorder (MDD)Kina
Kliniske forsøg med Psykoterapi
-
Yale UniversityNational Institute of Mental Health (NIMH)AfsluttetSeksuel minoritetsstressForenede Stater